In a photodynamic therapy (PDT)‐treated squamous cell carcinoma murine immune‐competent model, recombinant calreticulin (400 μg/mouse) injected peritumourally immediately after PDT was found to bind to mouse SCCVII tumour cells treated by PDT and rendered a significant improvement in tumour response to PDT from marginally curative to the solid levels of about 40% cure rates.111. The gene discussed is CALR; the disease is neoplasm.